Open AccessImpact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomised, multi-centre pilot study
Author(s) -
George L. Bakris,
Alex Smith,
Donald J. Richardson,
Elena Hung,
Richard A. Preston,
Ronald Goldberg,
Murray Epstein
Publication year - 2002
Publication title -
journal of human hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.737
H-Index - 95
eISSN - 1476-5527
pISSN - 0950-9240
DOI - 10.1038/sj.jhh.1001315
Subject(s) - medicine , microalbuminuria , amlodipine , apolipoprotein b , blood pressure , ace inhibitor , endocrinology , lipid profile , type 2 diabetes , benazepril , dihydropyridine , creatinine , cholesterol , diabetes mellitus , calcium , angiotensin converting enzyme
Microalbuminuria (MA) is associated with increased cardiovascular risk and lipid abnormalities in people with type 2 diabetes. ACE inhibitors and calcium channel blockers (CCBs) reduce MA and are neutral on total cholesterol and triglycerides. The effect of ACE inhibitors and CCBs on lipid subfractions such as Lp(a), apolipoprotein (apo) A1, apo B, and others, however, is unclear. The current study tests the hypothesis that a fixed-dose combination of an ACE inhibitor, benazepril (B) with the dihydropyridine CCB, amlodipine (A), will further reduce arterial pressure and reduce atherogenic lipid fractions compared to either agent alone.